CClinicalTrials.gg
CompletedNCT03045263PRTUpdated Jun 26, 2020

Pivotal Response Treatment (PRT) Telemedicine

An interventional study of Pivotal Response Treatment in Autism Spectrum Disorder, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 3 Years to 6 Years. Per ClinicalTrials.gov, last updated 2020-06-26.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
3 Years to 6 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the application of a modified version of PRT designed specifically as a parent-training model via telemedicine, with the goal of increasing access to empirically validated care. The project will feature an 18-week trial of parent training PRT via telemedicine in 12 cognitively able 3- to 6-year-old children with ASD. Intervention will focus on enhancing the following developmental skills: expressive and receptive language, play, and social interaction. Outcome measures will address changes in the aforementioned domains during structured observation and standardized assessment.

Read the detailed description

The purpose of this study is to evaluate the application of a modified version of PRT designed specifically as a parent-training model via telemedicine, with the goal of increasing access to empirically validated care. The project will feature an 18-week trial of parent training PRT via telemedicine in 12 cognitively able 3- to 6-year-old children with ASD. Intervention will focus on enhancing the following developmental skills: expressive and receptive language, play, and social interaction. Outcome measures will address changes in the aforementioned domains during structured observation and standardized assessment.

02

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • ASD
03

In context

Autism Spectrum Disorder

1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.

This study's enrollment of 7 is below the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.

Browse Autism Spectrum Disorder studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Fits age requirement: age 3-6 years
  • Have been diagnosed previously with ASD and meet criteria for ASD when characterized by research team.
  • be in good medical health
  • be cooperative with testing
  • english is a language spoken in the family
  • full scale IQ > 70

Exclusion criteria

Exclusion Criteria:

  • significant hearing loss or other severe sensory impairment
  • a fragile health status
  • a history of significant head trauma or serious brain or psychiatric illness
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Active comparator
    Pivotal Response Treatment

    Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis

    Behavioral: Pivotal Response Treatment

  • No intervention
    Waitlist Control

    Children in WL will be offered treatment following WL condition.

Interventions

  • BehavioralPivotal Response Treatment

    Behavioral intervention for autism

    Also known as: PRT

06

What researchers measure

Primary outcomes

  1. Behavioural Intervention Rating Scale (BIRS)

    Time frame: 10 weeks

Secondary outcomes

  1. Client Credibility Questionnaire (CCQ)

    Time frame: 10 weeks

07

Study locations

1 site
  • Yale Child Study Center
    New Haven, Connecticut 06512, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03045263
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Feb 7, 2017
Start date
Feb 2, 2017
Primary completion
May 3, 2018
Completion
May 3, 2018
Last update
Jun 26, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion